The U.S. Supreme Court has refused to take up Girardi Keese’s fight against turning over more than $10 million in proceeds from a 2012 settlement to the lead attorneys in multidistrict litigation involving the diabetes drug Avandia.
Plaintiffs firm Girardi Keese filed more than 4,000 cases against GlaxoSmithKline PLC alleging that Avandia increased the plaintiffs’ risk of heart failure. Most were in California state court, but 25 were in the multidistrict litigation, which is pending in the U.S. District Court for the Eastern District of Pennsylvania.
